Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Biological therapies targeting eosinophils have been shown to be effective in treating patients with severe eosinophilic asthma. Benralizumab (Fasenra, AstraZeneca) is a humanized monoclonal antibody binding to the alpha subunit of the interleukin-5 receptor, which rapidly depletes eosinophils via antibody-dependent cellular cytotoxicity. The aim of this Phase 1 study was to assess the safety, tolerability, and pharmacokinetics of benralizumab in healthy Chinese individuals.
Materials And Methods: In this randomized, single-blind study (NCT03928262), healthy Chinese adult participants aged 18 to 45 years, weighing 50 to 100 kg, were randomized 1:1:1 to receive a single subcutaneous (SC) injection of benralizumab 10 mg, 30 mg, or 100 mg in the upper arms on Day 1. Safety was monitored throughout the study (up to Day 85), and blood samples were taken to determine serum benralizumab concentrations and for detection of anti-drug antibody. A non-compartmental analysis was conducted to estimate the pharmacokinetic parameters.
Results: Thirty-six healthy participants were enrolled, 12 in each dose group (mean [SD] age 26 [6] years). Following a single SC injection of benralizumab, 13 adverse events were reported by 10 participants (28%), with one mild injection-site reaction assessed as related. The mean serum benralizumab concentrations increased in a dose proportional manner, followed by exponential decreases. The mean terminal half-lives were 15.1 days for the 10 mg dose, 14.4 days for the 30 mg dose, and 15.4 days for the 100 mg dose. All doses resulted in near-complete depletion of eosinophils on Day 2, which was maintained throughout the study to Day 85.
Conclusion: A single SC injection of benralizumab was well tolerated by healthy Chinese participants, with no new or unexpected safety findings. The pharmacokinetics of benralizumab in Chinese participants was dose-proportional and consistent with those of non-Chinese participants observed in previous studies.
Clinical Trial Registration: NCT03928262 (https://clinicaltrials.gov/ct2/show/NCT03928262).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885872 | PMC |
| http://dx.doi.org/10.2147/DDDT.S392155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of cardiovascular risks and carotid stiffening at ultrafast ultrasound imaging in young populations.
Eur Radiol
September 2025
Department of Ultrasound, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Objectives: To evaluate the predictive role of carotid stiffening, quantified using ultrafast pulse wave velocity (ufPWV), for assessing cardiovascular risk in young populations with no or elevated cardiovascular risk factors (CVRFs).
Materials And Methods: This study enrolled 180 young, apparently healthy individuals who underwent ufPWV measurements. They were classified into three groups: the CVRF-free group (n = 60), comprising current non-smokers with untreated blood pressure < 140/90 mmHg, fasting blood glucose (FBG) < 7.
Pharmacokinetic Study and Bioequivalence Evaluation of Two Sustained-Release Tablets of Tamsulosin in Healthy Chinese Subjects Under Fasting and Postprandial Conditions.
Clin Pharmacol Drug Dev
September 2025
Phase I Clinical Research Centre, Wuhan Pulmonary Hospital, Wuhan, China.
Tamsulosin is a highly selective α1A adrenergic receptor antagonist that can relax smooth muscles in the urethra, bladder neck, and prostate and improve urinary disorders. It is therefore widely used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. The aim of this study is to evaluate the pharmacokinetic (PK) characteristics and bioequivalence of 2 different formulations (tamsulosin sustained-release tablets and tamsulosin sustained-release capsules) in healthy Chinese subjects.
View Article and Find Full Text PDFStudying the relationship between allergo-inflammation and left atrium and pulmonary vein pathological changes in allergic asthma.
Allergol Immunopathol (Madr)
September 2025
Department of Pediatrics, Ankang Hospital of Traditional Chinese Medicine, Ankang, China;
Allergic asthma is an inflammatory airway disease influenced by genetic and environmental factors and orchestrated by imbalance between T helper 1 cell (Th1) and two immune responses. Inflammation contributes to pathological changes and remodeling in tissues such as the vascular, lung, heart, and beds. The purpose for this study was to evaluate the effects of allergic asthma on heart pathology and remodeling.
View Article and Find Full Text PDFImpact of mitral valve interventions on left ventricular hemodynamics: Insights into energy loss and flow dynamics.
JTCVS Open
August 2025
The State Key Laboratory of Nonlinear Mechanics, Institute of Mechanics, Chinese Academy of Sciences, Beijing, China.
Objectives: Left ventricular vortex dynamics play a crucial role in cardiac function but are significantly altered by mitral valve diseases or surgical interventions. Such hemodynamic changes may lead to maladaptive intracardiac vortices, potentially triggering pathways associated with progressive left ventricular remodeling and thrombosis. This study assessed left ventricular hemodynamics under both physiological and pathological conditions using a biohybrid in vitro platform, aiming to analyze the impact of these conditions on cardiac function.
View Article and Find Full Text PDFREM Density, Leg Movements, and REM Sleep without Atonia: Differentiating Type 1 from Type 2 Narcolepsy Through Polysomnographic Analysis, a Preliminary Study.
Nat Sci Sleep
September 2025
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, People's Republic of China.
Objective: This study aimed to identify distinct REM sleep characteristics that differentiate type 1 narcolepsy (NT1) from type 2 narcolepsy (NT2) using polysomnography (PSG), while acknowledging the need for future validation against other hypersomnia disorders.
Methods: A retrospective review included 31 patients with NT1, 21 patients with NT2, and 24 healthy participants. Each participant underwent overnight PSG and a subsequent multiple sleep latency test (MSLT) to assess REM sleep parameters including average REM density, neck myoclonus index, and leg movement index.